Eisai Co., Ltd. (OTCMKTS:ESALY – Get Free Report) passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $61.51 and traded as low as $61.00. Eisai shares last traded at $61.51, with a volume of 331,800 shares traded.
Eisai Price Performance
The stock has a fifty day moving average of $61.51 and a 200-day moving average of $61.51. The company has a quick ratio of 1.77, a current ratio of 2.20 and a debt-to-equity ratio of 0.10. The stock has a market capitalization of $17.64 billion, a price-to-earnings ratio of 70.70, a P/E/G ratio of 2.46 and a beta of 0.31.
Eisai Company Profile
Eisai Co, Ltd. is a research-driven global pharmaceutical company headquartered in Tokyo, Japan. Founded in 1941 by Toyoji Naito, Eisai focuses on the discovery, development, manufacture and commercialization of prescription medicines and related healthcare products. The company emphasizes neuroscience and oncology as core therapeutic areas and invests in both small-molecule and biologic research to address unmet medical needs.
Among its well-known products, Eisai developed and markets Aricept (donepezil), a widely used treatment for the symptoms of Alzheimer’s disease, and LENVIMA (lenvatinib), an oncology therapy for several tumor types.
See Also
- Five stocks we like better than Eisai
- 3 Under-the-Radar Defense Stocks With Record Backlogs
- This Korea ETF Has Soared, But the Rally May Not Be Over
- Why Guidewire’s Post-Earnings Plunge May Not Last
- Ride-Share Reckoning: Tesla Drives Into Uber’s Lane
Receive News & Ratings for Eisai Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eisai and related companies with MarketBeat.com's FREE daily email newsletter.
